Functional Imaging in Parkinson's Disease

Alain Dagher

doi:10.1055/s-2001-13116

Seminars in Neurology, Table of Contents

Semin Neurol 2001; 21(1): 023-032
DOI: 10.1055/s-2001-13116

Functional Imaging in Parkinson's Disease

Alain Dagher

Montréal Neurological Institute, McGill University, Montréal, Canada

Abstract

ABSTRACT

This article reviews the applications of functional neuroimaging with positron emission tomography (PET) and single photon emission computed tomography (SPECT) to the diagnosis and treatment of Parkinson's disease (PD). PET measurements with [

@affil1:¹

@affil8:⁸F]deoxyglucose to measure glucose metabolism or with various markers of the pre- and postsynaptic dopamine systems may distinguish idiopathic PD from other conditions presenting with an akinetic-rigid state. Moreover, PET has been used to gain new insights into mechanisms of cell death and the role of heredity in Parkinson's disease. Finally, we discuss the use of functional neuroimaging to study the role of the basal ganglia in movement and cognition in PD.

KEYWORD

Positron emission tomography - Parkinson's disease - basal ganglia

Full Text

References

REFERENCES

1 Raichle M E. Circulatory and metabolic correlates of brain function in normal humans. In: Mountcastle VB, ed. Handbook of Physiology, Sect 1, Vol. 5: The Nervous System. Bethesda, MD: American Physiological Society 1987: 643-674
2 Garnett E S, Nahmias C, Firnau G. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci . 1984; 174-179 (174-179)
3 Hoshi H, Kuwabara H, Leger G. 6-[¹⁸F]Fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab . 1993; 13 57-69
4 Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse . 1999; 34 313-318
5 Leger G, Gjedde A, Kuwabara H, Guttman M, Cumming P. Effect of catechol-O-methyltransferase inhibition on brain uptake of [¹⁸F]fluorodopa: implications for compartmental modelling and clinical usefulness. Synapse . 1998; 30 351-361
6 Tedroff J, Aquilonius S M, Laihinen A. Striatal kinetics of [¹¹C]-(+)-nomifensine and 6-[¹⁸F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Acta Neurol Scand . 1990; 81 24-30
7 Booij J, Tissingh G, Winogrodzka A, van Royen A E. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med . 1999; 26 171-182
8 Frey K A, Koeppe R A, Kilbourn M R. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol . 1996; 40 873-884
9 Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol . 1995; 294 577-583
10 Innis R B, Marek K L, Sheff K. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [¹²³I]beta-CIT. Mov Disord . 1999; 14 436-442
11 Ahlskog J E, Uitti R J, O'Connor M K. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord . 1999; 14 940-946
12 Dewey S L, Smith G S, Logan J. Striatal binding of the PET ligand ¹¹C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse . 1993; 13 350-356
13 Gorell J M, Ordidge R J, Brown G G. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease [published erratum appears in Neurology 1995;45:1420]. Neurology . 1995; 45 1138-1143
14 Stern M B, Braffman B H, Skolnick B E. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology . 1989; 39 1524-1526
15 Kraft E, Schwarz J, Trenkwalder C. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy?. Arch Neurol . 1999; 56 225-228
16 Schrag A, Kingsley D, Phatouros C. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry . 1998; 65 65-71
17 Savoiardo M, Girotti F, Strada L, Ciceri E. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm Suppl . 1994; 42 93-110
18 Gimenez-Roldan S, Mateo D, Benito C, Grandas F, Perez-Gilabert Y. Progressive supranuclear palsy and corticobasal ganglionic degeneration: differentiation by clinical features and neuroimaging techniques. J Neural Transm Suppl . 1994; 42 79-90
19 Eidelberg D. The metabolic landscape of Parkinson's disease. Adv Neurol . 1999; 80 87-97
20 Eidelberg D, Moeller J R, Kazumata K. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain . 1997; 120 1315-1324
21 Kazumata K, Antonini A, Dhawan V. Preoperative indicators of clinical outcome following stereotaxic pallidotomy. Neurology . 1997; 49 1083-1090
22 Eidelberg D, Takikawa S, Moeller J R. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol . 1993; 33 518-527
23 Gilman S, Koeppe R A, Junck L. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol . 1994; 36 166-175
24 De Volder G A, Francart J, Laterre C. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol . 1989; 26 239-247
25 Blin J, Baron J C, Dubois B. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol . 1990; 47 747-752
26 Nagahama Y, Fukuyama H, Turjanski N. Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. Mov Disord . 1997; 12 691-696
27 Kuwabara H, Cumming P, Yasuhara Y. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. J Nucl Med . 1995; 36 1226-1231
28 Fearnley J M, Lees A J. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain . 1995; 114 2283-2301
29 Morrish P K, Sawle G V, Brooks D J. Clinical and [¹⁸F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry . 1995; 59 597-600
30 Piccini P, Burn D J, Ceravolo R, Maraganore D, Brooks D J. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol . 1999; 45 577-582
31 Piccini P, Morrish P K, Turjanski N. Dopaminergic function in familial Parkinson's disease: a clinical and ¹⁸F-dopa positron emission tomography study. Ann Neurol . 1997; 41 222-229
32 Brooks D J, Ibanez V, Sawle G V. Differing patterns of striatal ¹⁸F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol . 1990; 28 547-555
33 Sawle G V, Brooks D J, Marsden C D, Frackowiak R S. Corticobasal degeneration: a unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain . 1991; 114 541-556
34 Seibyl J P, Marek K L, Quinlan D. Decreased single-photon emission computed tomographic [¹²³I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol . 1995; 38 589-598
35 Marek K L, Seibyl J P, Zoghbi S S. [¹²³I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology . 1996; 46 231-237
36 Guttman M, Burkholder J, Kish S J. [¹¹C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology . 1997; 48 1578-1583
37 Tedroff J, Ekesbo A, Rydin E, Langstrom B, Hagberg G. Regulation of dopaminergic activity in early Parkinson's disease. Ann Neurol . 1999; 46 359-365
38 Ishikawa T, Dhawan V, Kazumata K. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med . 1996; 37 1760-1765
39 Rinne J O, Laihinen A, Nagren K. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J Neurosci Res . 1990; 27 494-499
40 Rinne J O, Laihinen A, Ruottinen H. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [¹¹C]raclopride. J Neurol Sci . 1995; 132 156-161
41 Antonini A, Schwarz J, Oertel W H, Beer H F, Madeja U D, Leenders K L. [¹¹C]Raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology . 1994; 44 1325-1329
42 Ouchi Y, Kanno T, Okada H. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. Ann Neurol . 1999; 46 723-731
43 Shinotoh H, Inoue O, Hirayama K. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry . 1993; 56 467-472
44 Antonini A, Leenders K L, Vontobel P. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain . 1997; 120 2187-2195
45 Brooks D J, Ibanez V, Sawle G V. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with ¹¹C-raclopride and positron emission tomography. Ann Neurol . 1992; 31 184-192
46 Schwarz J, Tatsch K, Gasser T. ¹²³I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord . 1998; 13 16-19
47 Piccini P, Brooks D J, Bjorklund A. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci . 1999; 2 1137-1140
48 Kuhl D E, Minoshima S, Fessler J A. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol . 1996; 40 399-410
49 Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry . 1998; 65 155-163
50 Shinotoh H, Namba H, Yamaguchi M. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol . 1999; 46 62-69
51 Scatton B, Javoy Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res . 1983; 275 321-328
52 Vingerhoets F J, Snow B J, Lee C S, Schulzer M, Mak E, Calne D B. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol . 1994; 36 759-764
53 Vingerhoets F J, Snow B J, Tetrud J W, Langston J W, Schulzer M, Calne D B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol . 1994; 36 765-770
54 Morrish P K, Rakshi J S, Bailey D L, Sawle G V, Brooks D J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [¹⁸F]dopa PET. J Neurol Neurosurg Psychiatry . 1998; 64 314-319
55 Snow B J, Tooyama I, McGeer E G. Human positron emission tomographic [¹⁸F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol . 1993; 34 324-330
56 Rakshi J S, Uema T, Ito K. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease. A 3D [18F]dopa-PET study. Brain . 1999; 122 1637-1650
57 Middleton F A, Strick P L. Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive function. Science . 1994; 266 458-461
58 White N M. Mnemonic functions of the basal ganglia. Curr Opin Neurobiol . 1997; 7 164-169
59 Taylor A E, Saint Cyr A J, Lang A E. Frontal lobe dysfunction in Parkinson's disease: the cortical focus of neostriatal outflow. Brain . 1986; 109 845-883
60 Owen A M, James M, Leigh P N. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain . 1992; 115 1727-1751
61 Lange K W, Robbins T W, Marsden C D, James M, Owen A M, Paul G M. L-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) . 1992; 107 394-404
62 Jahanshahi M, Jenkins I H, Brown R G, Marsden C D, Passingham R E, Brooks D J. Self-initiated versus externally triggered movements: I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. Brain . 1995; 118 913-933
63 Jenkins I H, Fernandez W, Playford E D. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol . 1992; 32 749-757
64 Owen A M, Doyon J, Dagher A, Sadikot A, Evans A C. Abnormal basal ganglia outflow in Parkinson's disease identified with PET: implications for higher cortical functions. Brain . 1998; 121 949-965
65 Grafton S T, Waters C, Sutton J, Lew M F, Couldwell W. Pallidotomy increases activity of motor association cortex in Parkinson's disease: a positron emission tomographic study. Ann Neurol . 1995; 37 776-783
66 Grossman M, Crino P, Reivich M, Stern M B, Hurtig H I. Attention and sentence processing deficits in Parkinson's disease: the role of anterior cingulate cortex. Cereb Cortex . 1992; 2 513-525
67 Samuel M, Ceballos Baumann O A. Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements. An H₂O PET study. Brain . 1997; 120 1301-1312
68 Playford E D, Jenkins I H, Passingham R E, Nutt J, Frackowiak R S, Brooks D J. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol . 1992; 32 151-161
69 Samuel M, Ceballos-Baumann A O, Blin J. Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements: a PET study. Brain . 1997; 120 963-976
70 Rascol O, Sabatini U, Chollet F. Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine. Arch Neurol . 1992; 49 144-148
71 Limousin P, Greene J, Pollak P, Rothwell J, Benabid A L, Frackowiak R. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease. Ann Neurol . 1997; 42 283-291
72 Alexander G E, Crutcher M D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci . 1990; 13 266-271
73 Scott R, Gregory R, Hines N. Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease: a consecutive series of eight simultaneous bilateral and twelve unilateral procedures. Brain . 1998; 121 659-675
74 Lang A E, Lozano A, Tasker R, Duff J, Saint-Cyr J, Trepanier L. Neuropsychological and behavioral changes and weight gain after medial pallidotomy [letter]. Ann Neurol . 1997; 41 834-836
75 Dagher A, Doyon J, Owen A M, Boecker H, Samuel M, Brooks D J. Medial temporal lobe activation in Parkinson's disease during fronto-striatal tasks revealed by PET: evidence for cortical reorganization?. Mov Disord . 1998; 238 (238)
76 Georgiou N, Bradshaw J L, Iansek R, Phillips J G, Mattingley J B, Bradshaw J A. Reduction in external cues and movement sequencing in Parkinson's disease. J Neurol Neurosurg Psychiatry . 1994; 57 368-370
77 Ouchi Y, Yoshikawa E, Okada H. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography. Ann Neurol . 1999; 45 601-610